Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.

Sequential more cost-effective than standard triple therapy for H. pylori infection

14 Feb 2020

A 10-day or 14-day sequential therapy (ST) strategy is more cost-effective than a conventional triple therapy (TT) in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.

Researchers randomized patients who tested positive for H. pylori infection to treatment with 14-day TT (n=34), 10-day ST (n=34) or 14-day ST (n=35). Sequential treatment comprised lansoprazole 30 mg and amoxicillin 1,000 mg, both administered twice daily for 5 or 7 days, followed by lansoprazole 30 mg, clarithromycin 500 mg and tinidazole 500 mg, each given twice daily for another 5 or 7 days. Meanwhile standard TT consisted of lansoprazole 30 mg, clarithromycin 500 mg and amoxicillin 1,000 mg, administered twice daily for 14 days.

All patients underwent urea breath test at week 6 weeks after treatment discontinuation. Outcomes evaluated were eradication rates, adverse effects (AEs), compliance and cost-effectiveness.

Compared with the conventional TT group, both ST groups achieved higher eradication rates: 90 percent with 10-day ST and 96.7 percent with 14-day ST vs 63.3 percent with TT (p=0.001).

All treatment regimens were well-tolerated, with diarrhoea and abdominal pain being the most frequently reported AEs. There were no significant differences recorded in AE incidence, except for abdominal pain being greater in the TT group.

Finally, the cost-effectiveness ratio was 2,194 Egyptian pound (LE) for conventional TT, 1,241 LE for 10-day ST and 1,157 LE for 14-day ST. “The extra cost per patient for achieving eradication in one additional patient with 14-day ST instead of 10-day ST was 30 LE,” the researchers noted.

In light of the results, the researchers believe that ST might replace TT as a first-line treatment for H. pylori infection.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.